Patents Assigned to CYTOCHROMA
-
Patent number: 9066917Abstract: There is provided a method of producing a mixed metal compound comprising at least Mg2+ and at least Fe3+ having an aluminum content of less than 10000 ppm, having an average crystal size of less than 20 nm (200 A) comprising the steps of: (a) combining a Mg2+ salt and a Fe3+ salt with Na2CO3 and NaOH to produce a slurry, wherein the pH of the slurry is maintained at from 9 5 to 1 1, and wherein the Na2CO3 is provided at an excess of 0 to 4.0 moles than is required to complete the reaction (b) subjecting the slurry to mixing under conditions providing a power per unit volume of 0 03 to 1.6 kW/m3 (c) separating the mixed metal compound from the slurry, to obtain a crude product having a dry solid content of at least 10 wt % (d) drying the crude product either by (i) heating the crude product to a temperature of no greater than 150° C. and sufficient to provide a water evaporation rate of 0.Type: GrantFiled: March 24, 2014Date of Patent: June 30, 2015Assignee: CYTOCHROMA DEVELOPMENT INC.Inventors: Richard Jonathan Applewhite, James David Morrison, Maurice Sydney Newton, Nigel Peter Rhodes, Christopher John Rickard
-
Patent number: 8906888Abstract: The present invention provides novel 16,23-diene 25-oxime ether analogs of 1,25-dihydroxy vitamin D3, compositions comprising these compounds and methods of using these compounds as inhibitors of CYP24. In particular, the novel compound of the invention are useful for treating diseases which benefit from a modulation of the levels of 1,25-dihydroxy vitamin D3, for example, cell-proliferative disorders.Type: GrantFiled: April 25, 2006Date of Patent: December 9, 2014Assignees: Cytochroma Inc., Johns Hopkins UniversityInventors: Uttam Saha, Gary H. Posner, Mehmet Kahraman
-
Publication number: 20140205667Abstract: There is provided a method of producing a mixed metal compound comprising at least Mg2+ and at least Fe3 + having an aluminium content of less than 10000 ppm, having an average crystal size of less than 20 nm (200 A) comprising the steps of: (a) combining a Mg2+ salt and a Fe3 + salt with Na2CO3 and NaOH to produce a slurry, wherein the pH of the slurry is maintained at from 9 5 to 1 1, and wherein the Na2CO3 is provided at an excess of 0 to 4.0 moles than is required to complete the reaction (b) subjecting the slurry to mixing under conditions providing a power per unit volume of 0 03 to 1.6 kW/m3 (c) separating the mixed metal compound from the slurry, to obtain a crude product having a dry solid content of at least 10 wt % (d) drying the crude product either by (i) heating the crude product to a temperature of no greater than 150° C. and sufficient to provide a water evaporation rate of 0.Type: ApplicationFiled: March 24, 2014Publication date: July 24, 2014Applicant: CYTOCHROMA DEVELOPMENT INC.Inventors: Richard Jonathan Applewhite, James David Morrison, Maurice Sydney Newton, Nigel Peter Rhodes, Christopher John Rickard
-
Publication number: 20140120180Abstract: A mixed metal compound for pharmaceutical use is free from aluminium and has a phosphate binding capacity of at least 30%, by weight of the total weight of phosphate present, over a pH range of from 2-8. The compound is especially useful for treatment of hyperphosphataemia. The metals are preferably iron (III) and at least one of calcium, magnesium, lanthanum and cerium. A metal sulphate for pharmaceutical use is selected from at least one of calcium, lanthanum and cerium sulphate compounds and has a phosphate binding capacity of at least 30% by weight of the total phosphate present, over a pH range from 2-8.Type: ApplicationFiled: October 28, 2013Publication date: May 1, 2014Applicant: CYTOCHROMA DEVELOPMENT INC.Inventors: Norman Bryson Roberts, Maurice Webb Chester, Benjamin Joseph
-
Publication number: 20140113886Abstract: A stabilized 1,25-dihydroxyvitamin D2 composition which is particularly well suited for pharmaceutical formulations, pharmaceutical formulations of the 1,25-dihydroxyvitamin D2 composition, and a method of making the purified composition by purifying a crude 1,25-dihydroxyvitamin D2 from acetone/water, are disclosed.Type: ApplicationFiled: January 2, 2014Publication date: April 24, 2014Applicant: CYTOCHROMA INC.Inventor: Uttam Saha
-
Publication number: 20130323325Abstract: The present invention provides a composition comprising (i) a mixed metal compound containing at least one trivalent metal selected from iron (lll) and aluminium and at least one divalent metal selected from of magnesium, iron, zinc, calcium, lanthanum and cerium, (ii) xanthan gum (iii) at least one of (a) polyvinyl pyrrolidone (b) locust bean gum (c) methyl cellulose wherein the composition has been irradiated with ionising radiation in an amount of at least 4 kGy.Type: ApplicationFiled: February 3, 2011Publication date: December 5, 2013Applicant: CYTOCHROMA DEVELOPMENT INC.Inventors: Richard Jonathan Applewhite, Maurice Sydney Newton, Alexis John Toft
-
Patent number: 8592401Abstract: Methods and compositions comprising 1,25-dihydroxyvitamin D2 are disclosed. A method for lowering or maintaining lowered serum parathyroid hormone in human patients including administering to said patients an effective amount of 1,25-dihydroxyvitamin D2 to lower or maintain lowered serum parathyroid hormone levels is disclosed. Dosage forms and dosing regimens are also disclosed.Type: GrantFiled: April 25, 2008Date of Patent: November 26, 2013Assignees: Proventiv Therapeutics, LLC, Cytochroma Inc.Inventors: P. Martin Petkovich, Charles W. Bishop, Eric J. Messner, Keith H. Crawford
-
Patent number: 8568792Abstract: A mixed metal compound for pharmaceutical use is free from aluminium and has a phosphate binding capacity of at least 30%, by weight of the total weight of phosphate present, over a pH range of from 2-8. The compound is especially useful for treatment of hyperphosphataemia. The metals are preferably iron (III) and at least one of calcium, magnesium, lanthanum and cerium. A metal sulphate for pharmaceutical use is selected from at least one of calcium, lanthanum and cerium sulphate compounds and has a phosphate binding capacity of at least 30% by weight of the total phosphate present, over a pH range from 2-8.Type: GrantFiled: July 1, 2010Date of Patent: October 29, 2013Assignee: Cytochroma Development Inc.Inventors: Norman B Roberts, Maurice Webb, Benjamin J Rankin
-
Publication number: 20130178451Abstract: The method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies.Type: ApplicationFiled: November 19, 2012Publication date: July 11, 2013Applicants: PROVENTIV THERAPEUTICS, LLC, CYTOCHROMA INC.Inventors: CYTOCHROMA INC., PROVENTIV THERAPEUTICS, LLC
-
Publication number: 20130157987Abstract: This present disclosure is directed to novel prodrugs of activated vitamin D3 compounds. The prodrugs can be designed to have one or more beneficial properties, such as selective inhibition of the enzyme CYP24, low calcemic activity, and anti-proliferative activity. Specifically, these prodrugs are 1-deoxy prohormones of active Vitamin D analogs, e.g. analogs of calcitriol. This disclosure is also directed to pharmaceutical and diagnostic compositions containing the prodrugs of the invention, and to their medical use, particularly as prodrugs in the treatment and/or prevention of diseases.Type: ApplicationFiled: January 13, 2011Publication date: June 20, 2013Applicants: JOHNS HOPKINS UNIVERSITY, CYTOCHROMA INC.Inventors: Gary H. Posner, Lindsey C. Hess, Alvin S. Kalinda, Rachel D. Slack, Uttam Saha, P. Martin Petkovich
-
Publication number: 20130131022Abstract: A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.Type: ApplicationFiled: January 22, 2013Publication date: May 23, 2013Applicants: PROVENTIV THERAPEUTICS, LLC, CYTOCHROMA INC.Inventors: CYTOCHROMA INC., PROVENTIV THERAPEUTICS, LLC
-
Patent number: 8361488Abstract: A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.Type: GrantFiled: April 25, 2008Date of Patent: January 29, 2013Assignees: Cytochroma Inc., Proventiv Therapeutics, LLCInventors: Charles W. Bishop, Samir P. Tabash, Sammy Asiamah Agudoawu, Jay A. White, Keith H. Crawford, Eric J. Messner, P. Martin Petkovich
-
Patent number: 8329677Abstract: The a method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies.Type: GrantFiled: June 21, 2007Date of Patent: December 11, 2012Assignees: Cytochroma, Inc., Proventiv Therapeutics, LLCInventors: Charles W. Bishop, Keith H. Crawford, Eric J. Messner, Martin P. Petkovich, Christian F. Helvig
-
Publication number: 20120201864Abstract: There is provided a method of producing a mixed metal compound comprising at least Mg2+ and at least Fe+ having an aluminium content of less than 10000 ppm, having an average crystal size of less than 20 nm (200 A) comprising the steps of: (a) combining a Mg2+ salt and a Fe3+ salt with Na2CO3 and NaOH to produce a slurry, wherein the pH of the slurry is maintained at from 9 5 to 1 1, and wherein the Na2CO3 is provided at an excess of 0 to 4.0 moles than is required to complete the reaction (b) subjecting the slurry to mixing under conditions providing a power per unit volume of 0 03 to 1.6 kW/m3 (c) separating the mixed metal compound from the slurry, to obtain a crude product having a dry solid content of at least 10 wt % (d) drying the crude product either by (i) heating the crude product to a temperature of no greater than 150° C. and sufficient to provide a water evaporation rate of 0.Type: ApplicationFiled: August 2, 2010Publication date: August 9, 2012Applicant: CYTOCHROMA DEVELOPMENT INC.Inventors: Richard J. Applewhite, James D. Morrison, Maurice S. Newton, Nigel P. Rhodes, Christopher J. Rickard
-
Patent number: 8207149Abstract: A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.Type: GrantFiled: September 26, 2011Date of Patent: June 26, 2012Assignees: Cytochroma, Inc., Proventiv Therapeutics, LLCInventors: Samir P. Tabash, Jay A. White, Charles W. Bishop, Sammy A. Agudoawu, Eric J. Messner, P. Martin Petkovich
-
Publication number: 20120130133Abstract: Processes for preparing vitamin D2 derivatives and intermediates to vitamin D2 derivatives are disclosed. An improved photolysis process for the preparation of cis intermediate (I) from the trans starting material (II) are disclosed. Also disclosed is an improved process for the formation of a trans double bond at C22-C23 of the vitamin D2 derivative, which provides high selectivity of the desired trans double bond of compound (III) over the undesired cis double bond of compound (IIIA).Type: ApplicationFiled: November 25, 2009Publication date: May 24, 2012Applicant: CYTOCHROMA INC.Inventor: Uttam Saha
-
Publication number: 20120094396Abstract: Methods and compositions for measuring the amount of vitamin D derivatives are disclosed. Fluorescence Resonance Energy Transfer (FRET) in combination with a modified ligand-binding domain of the vitamin D receptor (LBD-VDR) to measure vitamin D derivatives are also disclosed.Type: ApplicationFiled: May 3, 2010Publication date: April 19, 2012Applicant: CYTOCHROMA INC.Inventors: P. Martin Petkovich, Christian F. Helvig
-
Publication number: 20120028926Abstract: This invention relates to methods and small molecules having a phosphate group that can be used to inhibit phosphate transport and to treat or prevent diseases that are related to disorders in the maintenance of normal serum phosphate levels.Type: ApplicationFiled: January 26, 2010Publication date: February 2, 2012Applicant: CYTOCHROMA INC.Inventors: Uttam Saha, Christian F. Helvig, P. Martin Petkovich
-
Patent number: 8106035Abstract: The present invention provides novel D-ring and side-chain analogs of 1?,25-dihydroxyvitamin D3, compositions comprising these compounds and methods of using these compounds as selective inhibitors of CYP24. In particular, the compounds of the invention are useful for treating diseases which benefit from a modulation of the levels of 1?,25-dihydroxyvitamin D3, for example, cell-proliferative disorders.Type: GrantFiled: December 18, 2003Date of Patent: January 31, 2012Assignee: Cytochroma Inc.Inventors: Gary H. Posner, Jae Kyoo Lee, Qiang Wang, Kenneth R. Crawford, Hong Woon Yang, Steven M. Silverman, Byung-Chul Suh, Jay A. White, Glenville Jones, Uttam Saha, Heung Bae Jeon
-
Publication number: 20120015916Abstract: A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.Type: ApplicationFiled: September 26, 2011Publication date: January 19, 2012Applicant: CYTOCHROMAInventors: Samir P. Tabash, Jay A. White, Charles W. Bishop, Sammy Asiamah Agudoawu